EP0775202A1 - Humane interleukinvarianten durch alternatives spleissen - Google Patents

Humane interleukinvarianten durch alternatives spleissen

Info

Publication number
EP0775202A1
EP0775202A1 EP95915509A EP95915509A EP0775202A1 EP 0775202 A1 EP0775202 A1 EP 0775202A1 EP 95915509 A EP95915509 A EP 95915509A EP 95915509 A EP95915509 A EP 95915509A EP 0775202 A1 EP0775202 A1 EP 0775202A1
Authority
EP
European Patent Office
Prior art keywords
exon
seq
human
mrna
pcr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95915509A
Other languages
English (en)
French (fr)
Other versions
EP0775202A4 (de
Inventor
William Alms
Barbara White
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Maryland at Baltimore
Original Assignee
University of Maryland at Baltimore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Maryland at Baltimore filed Critical University of Maryland at Baltimore
Publication of EP0775202A1 publication Critical patent/EP0775202A1/de
Publication of EP0775202A4 publication Critical patent/EP0775202A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP95915509A 1994-03-30 1995-03-30 Humane interleukinvarianten durch alternatives spleissen Withdrawn EP0775202A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US21983194A 1994-03-30 1994-03-30
US219831 1994-03-30
US22401094A 1994-04-06 1994-04-06
US224010 1994-04-06
PCT/US1995/004094 WO1995027052A1 (en) 1994-03-30 1995-03-30 Human interleukin variants generated by alternative splicing

Publications (2)

Publication Number Publication Date
EP0775202A1 true EP0775202A1 (de) 1997-05-28
EP0775202A4 EP0775202A4 (de) 1999-07-14

Family

ID=26914296

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95915509A Withdrawn EP0775202A4 (de) 1994-03-30 1995-03-30 Humane interleukinvarianten durch alternatives spleissen

Country Status (5)

Country Link
EP (1) EP0775202A4 (de)
JP (1) JPH09511400A (de)
AU (1) AU2237395A (de)
CA (1) CA2186854A1 (de)
WO (1) WO1995027052A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997008321A1 (en) 1995-08-24 1997-03-06 Magainin Pharmaceuticals Inc. Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
FR2775984B1 (fr) * 1998-03-11 2006-09-15 Bioscreen Therapeutics Sa Criblage differentiel qualitatif
US6881571B1 (en) 1998-03-11 2005-04-19 Exonhit Therapeutics S.A. Qualitative differential screening
US5986059A (en) 1996-06-14 1999-11-16 Bayer Corporation T-cell selective interleukin-4 agonists
US6335426B1 (en) 1996-06-14 2002-01-01 Bayer Corporation T-cell selective interleukin-4 agonists
US6028176A (en) 1996-07-19 2000-02-22 Bayer Corporation High-affinity interleukin-4 muteins

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CIARDELLI T.L. ET AL.: "Structural sudies of interleukin 2" PEPTIDES: STRUCTURE & FUNCTION: PROCEEDINGS OF THE AMERICAN PEPTIDE SYMPOSIUM. EDS: DEBER C.M., HRUBY V.J., KOPPLE K.D.; PUB: PIERCE CHEMICAL CO, ROCKFORD (IL) USA, vol. 9, 1985, pages 75-78, XP002100685 *
See also references of WO9527052A1 *
SORG R. ET AL.: "Expression of alternatively spliced mRNAs for IL-2, IL-4, IL-5, G-CSF, and GM-CSF" SYMPOSIUM ON SECRETED CYTOKINES II; ABSTRACTS OF THE II INTERNATIONAL SYMPOSIUM ON CYTOKINES IN HEMOPOIESIS, ONCOLOGY AND AIDS, HANNOVER 12-22 JUNE 1991, XP002100687 *
SORG R. ET AL.: "Rapid and sensitive mRNA phenotyping for interleukins (IL-1 to IL-6) and Colony-stimulating Factors (G-CSF and GM-CSF) by reverse transcription and subsequent polymerase chain reaction" EXPERIMENTAL HEMATOLOGY, vol. 19, no. 9, 1991, pages 882-887, XP002100686 *

Also Published As

Publication number Publication date
JPH09511400A (ja) 1997-11-18
AU2237395A (en) 1995-10-23
CA2186854A1 (en) 1995-10-12
WO1995027052A1 (en) 1995-10-12
EP0775202A4 (de) 1999-07-14

Similar Documents

Publication Publication Date Title
Alms et al. Generation of a variant of human interleukin-4 by alternative splicing
JP2568394B2 (ja) 哺乳動物インターロイキン−４活性を示すポリペプチドをコードするヌクレオチド配列からなる核酸
Atamas et al. An alternative splice variant of human IL-4, IL-4 delta 2, inhibits IL-4-stimulated T cell proliferation.
Kupper et al. Human keratinocytes contain mRNA indistinguishable from monocyte interleukin 1 alpha and beta mRNA. Keratinocyte epidermal cell-derived thymocyte-activating factor is identical to interleukin 1.
Kikutani et al. Molecular structure of human lymphocyte receptor for immunoglobulin E
AU760224B2 (en) Isolated nucleic acid molecules which encode T cell inducible factors (TIFs), the proteins encoded, and uses thereof
Burd et al. Activated mast cells produce interleukin 13.
CA2125763C (en) P40 homodimer of interleukin-12
US5319071A (en) Soluble interleukin-1 receptors
IE61563B1 (en) Interleukin-1 receptors
Choi et al. Molecular and functional characterization of chickenIL-15
EP0571442A1 (de) Cytokin-induzierbares protein tsg-14, seine kodierende dna und ihre verwendung
JP2009149651A (ja) リンパ球化学誘引因子およびその用途
WO1991018982A1 (en) Type ii interleukin-1 receptors
WO1994004680A9 (en) Human interleukin-13
JPH07508179A (ja) ヒトインターロイキン−１３
CA2293735A1 (en) Lag-3 splice variants
Yutaka et al. Role of ATL-derived factor (ADF) in the normal and abnormal cellular activation: involvement of dithiol related reduction
Karlen et al. Biological and molecular characteristics of interleukin-5 and its receptor
US6040426A (en) Human Th2 specific protein
JPH064674B2 (ja) ヒトインタ−ロイキン−１遺伝子のクロ−ニング及び特性化
EP0775202A1 (de) Humane interleukinvarianten durch alternatives spleissen
Denoroy et al. Interleukin 4 and interferons α and γ regulate FcϵR2/CD23 mRNA expression on normal human B cells
Hasegawa et al. Monoclonal antibodies to epitope of CD45R (B220) inhibit interleukin 4-mediated B cell proliferation and differentiation
US5766943A (en) DNA sequences for soluble form of CD23

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19961028

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: LT;SI

A4 Supplementary search report drawn up and despatched

Effective date: 19990601

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19990818